Global Cardiac Arrest Treatment Market – An Overview
World over cardiovascular diseases are seeing an increase in incidence. Additionally, certain underlying issues such as agonal breathing or apnea, which are known to cause cardiac arrest, are seeing an increase in numbers of people affected. Some of the reasons include lifestyle choices – alcohol and tobacco use, lack of exercise and a hectic work schedule.
As per Transparency Market Research, this will lead to growth in the global cardiac arrest treatment market over the forecast period of 2019 to 2020. A number of factors would underlie this growth and lead to generation of lucrative growth opportunities. Besides, they will pull up the market worth by a considerable value.
To understand what is driving the market forward, it is significant to note the following:
Cardiac Arrest Treatment Market - Snapshot
Cardiac arrest is defined as a sudden and abrupt loss of heart function, consciousness, and apnea or agonal breathing. It is a heterogeneous condition in terms of underlying pathology. It results from an electrical disturbance in the heart because of a problem with electrical signals. The disturbance leads to disruption in pumping action and stoppage of blood flow to the body. Cardiac arrest is often fatal. If appropriate steps are not taken immediately, sudden cardiac arrest can lead to death. The most common cause of a cardiac arrest is abnormal heart rhythm such as ventricular tachycardia or ventricular fibrillation. Other causes of cardiac arrest include thickened heart muscles (cardiomyopathy), heart medications, electrical abnormalities, blood vessel abnormalities, recreational drug use, and scarring of the heart tissue.
Obesity, diabetes mellitus, smoking, high cholesterol, high blood pressure, and sedentary lifestyles are the primary causes of heart failure and cardiac arrest. Rise in the number of people afflicted by these diseases is projected to drive demand for cardiac arrest treatment. According to the American Heart Association’s 2017 Heart Diseases and Stroke Statistics update, the number of people diagnosed with heart failure is increasing and projected to rise by 46% by 2030, resulting in more than 8 million people with heart failure. There are 22 million people living with congestive heart failure across the world and additional 2 million people are diagnosed every year. According to the American Heart Association, congestive heart failure is one of the leading causes of death in the U.S., accounting for 8.5% of the total population. According to the World Journal of Cardiovascular Diseases, more than 7 million deaths occur due to sudden cardiac arrest across the globe each year. Sudden cardiac death accounts for about 20% of all mortalities in the West. According to the U.S. National Library of Medicine of the National Institutes of Health, 40% to 50% of all cardiovascular deaths are sudden cardiac deaths (SCDs) and nearly 80% of these are caused by ventricular tachyarrhythmia. Therefore, about 6 million sudden cardiac deaths occur each year due to ventricular tachyarrhythmia. The overall prevalence of first degree atrioventricular block among the adult population in the U.S. is 3.7%. Prevalence of atrioventricular block is higher in patients with coronary heart diseases. Dual CRT pacemakers are implanted due to symptomatic bradycardia, which is caused by sick sinus syndrome or atrioventricular block or both. Untreated atrioventricular block will not only lead to heart failure, but also sudden cardiac death. However, stringent regulations for medical devices required for the treatment of cardiac arrest are expected to restrain the market during the forecast period.
The global cardiac arrest treatment market has been segmented based on treatment, sales channel, and region. In terms of treatment, the medical devices segment held major market share in 2018 and the trend is projected to continue during the forecast period. The beta blockers sub-segment is anticipated to dominate the drugs segment from 2019 to 2027. In terms of sales channel, the hospitals segment is likely to lead the global cardiac arrest treatment market during the forecast period.
Geographically, North America dominated the global cardiac arrest treatment market in 2018, accounting for the largest share. The region was the largest market for cardiac arrest treatment due to high adoption rate of CRT for cardiac arrest treatment among cardiologists and heart specialists and presence of large number of AED centers. Moreover, increase in incidence of cardiovascular disorders and advancements in medical devices for the treatment of cardiac arrest drive the cardiac arrest treatment market in North America. The market in Asia Pacific is expected to expand at a high CAGR from 2019 to 2027. Asia Pacific comprises major economies such as China, Japan, India, Australia, South Korea, and New Zealand. The cardiac arrest treatment market in Asia Pacific is growing rapidly compared to Europe and North America, which have shown stagnant growth in the past few years. Factors contributing to strong market growth in Asia Pacific are increase in incidence of sudden cardiac arrest (SCA), large patient base, rise in purchase of AEDs for organizational and corporate defibrillation programs, over the counter availability of AEDs, increase in disposable income, and subsequent spending on health care.
Key players operating in the global cardiac arrest treatment market include Amgen, Inc., Pfizer, Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Abbott, Bayer AG, Koninklijke Philips N.V., GE Healthcare, Physio-Control, Inc. (Stryker), Boston Scientific Corporation, Cardiac Science Corporation (Aurora Capital Group), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
The global Cell Expansion Market was worth US$ US$7.7 bn and is projected to reach a value of US$26 bn by the end of 2024
Cell Expansion Market is anticipated to grow at a CAGR of 14.70% during the forecast period
North America accounted for a major share of the global Cell Expansion Market
Rising onus on the innovative work exercises on the cell-based treatments and rising GMP accreditations for creation offices for cell treatment are likewise significant for driving the development of the worldwide cell expansion market
Key players in the global Cell Expansion Market include Cell Signaling Technology, Inc., Terumo Corporation, GE Healthcare, STEMCELL Technologies, Takara Bio, Inc., Bio-Techne (R&D Systems), Octane Biotech, Inc., Dickinson and Company, Merck Millipore (Merck KGaA), Corning Incorporated, Eppendorf AG, PeproTech, Inc., Danaher Corporation (Pall Corporation), Lonza Group, Becton
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Global Cardiac Arrest Treatment Market Size (US$ Mn) and Distribution, by Region, 2019 and 2027
3.2. Global Cardiac Arrest Treatment Market: Market Snapshot
4. Market Overview
4.1. Global Cardiac Arrest Treatment Market: Treatment Overview
4.2. Global Cardiac Arrest Treatment Market: Key Industry Developments
4.3. Market Dynamics
4.4. Drivers and Restraints Snapshot Analysis
4.5. Drivers
4.5.1. Rise in prevalence of congestive heart failure (CHF)
4.5.2. Government initiatives
4.6. Restraints
4.6.1. Low availability of cardiac arrest treatment in emerging countries
4.6.2. Growth of the generic drugs industry
4.7. Opportunities
4.8. Global Cardiac Arrest Treatment Market Revenue Projections (US$ Mn), 2017–2027
5. Key Insights
5.1. Incidence Rate of Cardiac Arrest In Key Countries
5.2. Technological Advancements in Medical Devices for Cardiac Arrest Treatment
5.3. Treatment Usage Pattern (Three-Phase Model of Cardiac Arrest)
5.4. Promising Treatments in Clinical Development: Cardiac Arrest
5.5. Annual cost of prehospital equipment per patient used to treat OHCA (Out- of Hospital Cardiac Arrest)
5.6. Key Merger and Acquisition
5.7. Research and Development Strategies for Key Companies
5.8. Pipeline Analysis for Cardiac Arrest Therapeutics
6. Global Cardiac Arrest Treatment Market Analysis, by Treatment
6.1. Introduction
6.2. Global Cardiac Arrest Treatment Market Size and Forecast, by Treatment
6.2.1. Drugs
6.2.1.1. Vasopressors
6.2.1.2. Anti-arrhythmic Drugs
6.2.1.3. Anticholinergic Drugs
6.2.1.4. Corticosteroids
6.2.1.5. Fibrinolytic Drugs
6.2.1.6. Beta Blockers
6.2.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
6.2.2. Medical Devices
6.2.2.1. Defibrillators
6.2.2.2. Cardiac Resynchronization Therapy (CRT)
6.2.2.3. Others
6.3. Global Cardiac Arrest Treatment Market Analysis, by Treatment
6.4. Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Treatment
7. Global Cardiac Arrest Treatment Market Analysis, by Sales Channel
7.1. Introduction
7.2. Global Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
7.2.1. Hospitals
7.2.2. Independent Pharmacies
7.2.3. Others
7.3. Global Cardiac Arrest Treatment Market Analysis, by Sales Channel
7.4. Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Sales Channel
8. Global Cardiac Arrest Treatment Market Analysis, by Region
8.1. Global Cardiac Arrest Treatment Market Size and Forecast, by Region, 2017–2027
8.1.1. North America
8.1.2. Europe
8.1.3. Asia Pacific
8.1.4. Latin America
8.1.5. Middle East & Africa
8.2. Global Cardiac Arrest Treatment Market Analysis, by Region
8.3. Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Region
9. North America Cardiac Arrest Treatment Market Analysis
9.1. North America Cardiac Arrest Treatment Market
9.2. North America Cardiac Arrest Treatment Market Overview
9.3. North America Cardiac Arrest Treatment Market Size and Forecast, by Treatment
9.3.1. Drugs
9.3.1.1. Vasopressors
9.3.1.2. Anti-arrhythmic Drugs
9.3.1.3. Anticholinergic Drugs
9.3.1.4. Corticosteroids
9.3.1.5. Fibrinolytic Drugs
9.3.1.6. Beta Blockers
9.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
9.3.2. Medical Devices
9.3.2.1. Defibrillators
9.3.2.2. Cardiac Resynchronization Therapy (CRT)
9.3.2.3. Others
9.4. North America Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
9.4.1. Hospitals
9.4.2. Independent Pharmacies
9.4.3. Others
9.5. North America Cardiac Arrest Treatment Market Forecast, by Country
9.5.1. U.S.
9.5.2. Canada
9.6. North America Cardiac Arrest Treatment Market Attractiveness Analysis
9.6.1. By Treatment
9.6.2. By Sales Channel
9.6.3. By Country
10. Europe Cardiac Arrest Treatment Market Analysis
10.1. Europe Cardiac Arrest Treatment Market
10.2. Europe Cardiac Arrest Treatment Market Overview
10.3. Europe Cardiac Arrest Treatment Market Size and Forecast, by Treatment
10.3.1. Drugs
10.3.1.1. Vasopressors
10.3.1.2. Anti-arrhythmic Drugs
10.3.1.3. Anticholinergic Drugs
10.3.1.4. Corticosteroids
10.3.1.5. Fibrinolytic Drugs
10.3.1.6. Beta Blockers
10.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
10.3.2. Medical Devices
10.3.2.1. Defibrillators
10.3.2.2. Cardiac Resynchronization Therapy (CRT)
10.3.2.3. Others
10.4. Europe Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
10.4.1. Hospitals
10.4.2. Independent Pharmacies
10.4.3. Others
10.5. Europe Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
10.5.1. U.K.
10.5.2. France
10.5.3. Germany
10.5.4. Spain
10.5.5. Italy
10.5.6. Rest of Europe
10.6. Europe Cardiac Arrest Treatment Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By Sales Channel
10.6.3. By Country/Sub-region
11. Asia Pacific Cardiac Arrest Treatment Market Analysis
11.1. Asia Pacific Cardiac Arrest Treatment Market Key Findings
11.2. Asia Pacific Cardiac Arrest Treatment Market Overview
11.3. Asia Pacific Cardiac Arrest Treatment Market Size and Forecast, by Treatment
11.3.1. Drugs
11.3.1.1. Vasopressors
11.3.1.2. Anti-arrhythmic Drugs
11.3.1.3. Anticholinergic Drugs
11.3.1.4. Corticosteroids
11.3.1.5. Fibrinolytic Drugs
11.3.1.6. Beta Blockers
11.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
11.3.2. Medical Devices
11.3.2.1. Defibrillators
11.3.2.2. Cardiac Resynchronization Therapy (CRT)
11.3.2.3. Others
11.4. Asia Pacific Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
11.4.1. Hospitals
11.4.2. Independent Pharmacies
11.4.3. Others
11.5. Asia Pacific Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
11.5.1. China
11.5.2. India
11.5.3. Japan
11.5.4. Australia & New Zealand
11.5.5. Rest of Asia Pacific
11.6. Asia Pacific Cardiac Arrest Treatment Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By Sales Channel
11.6.3. By Country/Sub-region
12. Latin America Cardiac Arrest Treatment Market Analysis
12.1. Latin America Cardiac Arrest Treatment Market Key Findings
12.2. Latin America Cardiac Arrest Treatment Market Overview
12.3. Latin America Cardiac Arrest Treatment Market Size and Forecast, by Treatment
12.3.1. Drugs
12.3.1.1. Vasopressors
12.3.1.2. Anti-arrhythmic Drugs
12.3.1.3. Anticholinergic Drugs
12.3.1.4. Corticosteroids
12.3.1.5. Fibrinolytic Drugs
12.3.1.6. Beta Blockers
12.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
12.3.2. Medical Devices
12.3.2.1. Defibrillators
12.3.2.2. Cardiac Resynchronization Therapy (CRT)
12.3.2.3. Others
12.4. Latin America Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
12.4.1. Hospitals
12.4.2. Independent Pharmacies
12.4.3. Others
12.5. Latin America Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
12.5.1. Brazil
12.5.2. Mexico
12.5.3. Rest of Latin America
12.6. Latin America Cardiac Arrest Treatment Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By Sales Channel
12.6.3. By Country/Sub-region
13. Middle East & Africa Cardiac Arrest Treatment Market Analysis
13.1. Middle East & Africa Cardiac Arrest Treatment Market
13.2. Middle East & Africa Cardiac Arrest Treatment Market Overview
13.3. Middle East & Africa Cardiac Arrest Treatment Market Size and Forecast, by Treatment
13.3.1. Drugs
13.3.1.1. Vasopressors
13.3.1.2. Anti-arrhythmic Drugs
13.3.1.3. Anticholinergic Drugs
13.3.1.4. Corticosteroids
13.3.1.5. Fibrinolytic Drugs
13.3.1.6. Beta Blockers
13.3.1.7. Others (sodium bicarbonate, crystalloids, colloids, etc.)
13.3.2. Medical Devices
13.3.2.1. Defibrillators
13.3.2.2. Cardiac Resynchronization Therapy (CRT)
13.3.2.3. Others
13.4. Middle East & Africa Cardiac Arrest Treatment Market Size and Forecast, by Sales Channel
13.4.1. Hospitals
13.4.2. Independent Pharmacies
13.4.3. Others
13.5. Middle East & Africa Cardiac Arrest Treatment Market Forecast, by Country/Sub-region
13.5.1. GCC Countries
13.5.2. South Africa
13.5.3. Rest of Middle East & Africa
13.6. Middle East & Africa Cardiac Arrest Treatment Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By Sales Channel
13.6.3. By Country/Sub-region
14. Competition Landscape
14.1. Company Profiles
14.1.1. Amgen, Inc.
14.1.1.1. Overview (HQ, Employee Strength, Business Segments)
14.1.1.2. Financials
14.1.1.3. Recent Developments
14.1.1.4. Strategy
14.1.2. Pfizer, Inc.
14.1.2.1. Overview (HQ, Employee Strength, Business Segments)
14.1.2.2. Financials
14.1.2.3. Recent Developments
14.1.2.4. Strategy
14.1.3. Johnson & Johnson
14.1.3.1. Overview (HQ, Employee Strength, Business Segments)
14.1.3.2. Financials
14.1.3.3. Recent Developments
14.1.3.4. Strategy
14.1.4. Novartis AG
14.1.4.1. Overview (HQ, Employee Strength, Business Segments)
14.1.4.2. Financials
14.1.4.3. Recent Developments
14.1.4.4. Strategy
14.1.5. Bristol-Myers Squibb Company
14.1.5.1. Overview (HQ, Employee Strength, Business Segments)
14.1.5.2. Financials
14.1.5.3. Recent Developments
14.1.5.4. Strategy
14.1.6. Abbott
14.1.6.1. Overview (HQ, Employee Strength, Business Segments)
14.1.6.2. Financials
14.1.6.3. Recent Developments
14.1.6.4. Strategy
14.1.7. Bayer AG
14.1.7.1. Overview (HQ, Employee Strength, Business Segments)
14.1.7.2. Financials
14.1.7.3. Recent Developments
14.1.7.4. Strategy
14.1.8. Koninklijke Philips N.V
14.1.8.1. Overview (HQ, Employee Strength, Business Segments)
14.1.8.2. Financials
14.1.8.3. Recent Developments
14.1.8.4. Strategy
14.1.9. GE Healthcare
14.1.9.1. Overview (HQ, Employee Strength, Business Segments)
14.1.9.2. Financials
14.1.9.3. Recent Developments
14.1.9.4. Strategy
14.1.10. Physio-Control, Inc. (Stryker)
14.1.10.1. Overview (HQ, Employee Strength, Business Segments)
14.1.10.2. Financials
14.1.10.3. Recent Developments
14.1.10.4. Strategy
14.1.11. Boston Scientific Corporation
14.1.11.1. Overview (HQ, Employee Strength, Business Segments)
14.1.11.2. Financials
14.1.11.3. Recent Developments
14.1.11.4. Strategy
14.1.12. Cardiac Science Corporation (Aurora Capital Group)
14.1.12.1. Overview (HQ, Employee Strength, Business Segments)
14.1.12.2. Financials
14.1.12.3. Recent Developments
14.1.12.4. Strategy
14.1.13. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
14.1.13.1. Overview (HQ, Employee Strength, Business Segments)
14.1.13.2. Financials
14.1.13.3. Recent Developments
14.1.13.4. Strategy
List of Tables
TABLE 1 Prevalence Rate of Cardiac Arrest In Key Countries
TABLE 2 Promising Treatments in Clinical Development: Cardiac Arrest, by Phase 2 Drugs
TABLE 3 Promising Treatments in Clinical Development: Cardiac Arrest, by Phase 3 and Phase 4 Drugs
TABLE 4 Annual cost of prehospital equipment per patient used to treat OHCA (Out- of Hospital Cardiac Arrest)
TABLE 5 Cost incurred to cardiac arrest patients
TABLE 6 Key Merger and Acquisition (1/2)
TABLE 7 Key Merger and Acquisition (2/2)
TABLE 8 Percent of Heart Failure Trials, by Phase and Location
TABLE 9 Percent of Heart Failure Trials, by Phase and Companies
TABLE 10 Pipeline Analysis for Cardiovascular Disorders Therapeutics (1/5)
TABLE 11 Pipeline Analysis for Cardiovascular Disorders Therapeutics (2/5)
TABLE 12 Pipeline Analysis for Cardiovascular Disorders Therapeutics (3/5)
TABLE 13 Pipeline Analysis for Cardiovascular Disorders Therapeutics (4/5)
TABLE 14 Pipeline Analysis for Cardiovascular Disorders Therapeutics (5/5)
TABLE 15 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 16 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 17 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 18 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 19 Global Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Region, 2017–2027
TABLE 20 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country, 2017–2027
TABLE 21 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 22 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 23 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 24 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 25 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 26 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 27 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 28 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 29 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 30 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 31 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 32 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 33 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 34 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 35 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 36 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 37 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 38 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 39 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
TABLE 40 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027
TABLE 41 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Treatment, 2017–2027
TABLE 42 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Drugs, 2017–2027
TABLE 43 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Medical Devices, 2017–2027
TABLE 44 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, by Sales Channel, 2017–2027
List of Figures
FIG. 1 Global Cardiac Arrest Treatment Market Size (US$ Mn), 2017 and 2026
FIG. 2 Global Cardiac Arrest Treatment Market Snapshot
FIG. 3 Global Cardiac Arrest Treatment Market Size (US$ Mn) Forecast, 2017–2027
FIG. 4 Global Cardiac Arrest Treatment Market
FIG. 5 Global Cardiac Arrest Treatment Market
FIG. 6 Global Cardiac Arrest Treatment Market
FIG. 7 Global Cardiac Arrest Treatment Market
FIG. 8 Global Cardiac Arrest Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 9 Global Cardiac Arrest Treatment Market Value Share Analysis, by Drugs, 2018 and 2027
FIG. 10 Global Cardiac Arrest Treatment Market Value Share Analysis, by Medical Devices, 2018 and 2027
FIG. 11 Global Cardiac Arrest Treatment Market Revenue (US$ Mn) Forecast, by Vasopressors, 2017–2027
FIG. 12 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Anti-arrhythmic Drugs, 2017–2027
FIG. 13 Global Cardiac Arrest Treatment Market Revenue (US$ Mn) Forecast, by Anticholinergic Drugs, 2017–2027
FIG. 14 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Corticosteroids, 2017–2027
FIG. 15 Global Cardiac Arrest Treatment Market Revenue (US$ Mn) Forecast, by Fibrinolytic Drugs, 2017–2027
FIG. 16 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Beta Blockers, 2017–2027
FIG. 17 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Others, 2017–2027
FIG. 18 Global Cardiac Arrest Treatment Market Revenue (US$ Mn) Forecast, by Defibrillators, 2017–2027
FIG. 19 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Cardiac Resynchronization Therapy (CRT), 2017–2027
FIG. 20 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Others, 2017–2027
FIG. 21 Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Drugs, 2017–2025
FIG. 22 Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Medical Devices, 2017-2025
FIG. 23 Global Cardiac Arrest Treatment Market Value Share Analysis, by Sales Channel, 2017 and 2025
FIG. 24 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Hospital, 2017–2027
FIG. 25 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Independent Pharmacies, 2017–2027
FIG. 26 Global Cardiac Arrest Treatment Market Revenue (US$ Mn), by Others, 2017–2027
FIG. 27 Global Cardiac Arrest Treatment Market Attractiveness Analysis, by Sales Channel 2017–2025
FIG. 28 Global Cardiac Arrest Treatment Market Value Share, by Region, 2018 and 2027
FIG. 29 Global Cardiac Arrest Treatment Market Attractiveness, by Region, 2019–2027
FIG. 30 North America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, 2019–2027
FIG. 31 North America Cardiac Arrest Treatment Market Value Share, by Country, 2018 and 2027
FIG. 32 North America Cardiac Arrest Treatment Market Attractiveness, by Country, 2019–2027
FIG. 33 North America Cardiac Arrest Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 34 North America Cardiac Arrest Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 35 North America Cardiac Arrest Treatment Market Value Share Analysis, by Drugs, 2018 and 2027
FIG. 36 North America Cardiac Arrest Treatment Market Value Share Analysis, by Medical Devices, 2018 and 2027
FIG. 37 North America Cardiac Arrest Treatment Market Value Share Analysis, by Sales Channel, 2018 and 2027
FIG. 38 North America Cardiac Arrest Treatment Market Attractiveness, by Sales Channel, 2019–2027
FIG. 39 Europe Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, 2017–2027
FIG. 40 Europe Cardiac Arrest Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 41 Europe Cardiac Arrest Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 42 Europe Cardiac Arrest Treatment Market Value Share, by Treatment, 2018 and 2027
FIG. 43 Europe Cardiac Arrest Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 44 Europe Cardiac Arrest Treatment Market Value Share, by Drugs, 2018 and 2027
FIG. 45 Europe Cardiac Arrest Treatment Market Value Share, by Medical Devices, 2018 and 2027
FIG. 46 Europe Cardiac Arrest Treatment Market Value Share, by Sales Channel, 2018 and 2027
FIG. 47 Europe Cardiac Arrest Treatment Market Attractiveness, by Sales Channel, 2019–2027
FIG. 48 Asia Pacific Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, 2019–2027
FIG. 49 Asia Pacific Cardiac Arrest Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 50 Asia Pacific Cardiac Arrest Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 51 Asia Pacific Cardiac Arrest Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 52 Asia Pacific Cardiac Arrest Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 53 Asia Pacific Cardiac Arrest Treatment Market Value Share Analysis, by Drugs, 2018 and 2027
FIG. 54 Asia Pacific Cardiac Arrest Treatment Market Value Share Analysis, by Medical Devices, 2018 and 2027
FIG. 55 Asia Pacific Cardiac Arrest Treatment Market Value Share Analysis, by Sales Channel, 2018 and 2027
FIG. 56 Asia Pacific Cardiac Arrest Treatment Market Attractiveness, by Sales Channel, 2019–2027
FIG. 57 Latin America Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, 2017–2027
FIG. 58 Latin America Cardiac Arrest Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 59 Latin America Cardiac Arrest Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 60 Latin America Cardiac Arrest Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 61 Latin America Cardiac Arrest Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 62 Latin America Cardiac Arrest Treatment Market Value Share Analysis, by Drugs, 2018 and 2027
FIG. 63 Latin America Cardiac Arrest Treatment Market Value Share Analysis, by Medical Devices, 2018 and 2027
FIG. 64 Latin America Cardiac Arrest Treatment Market Value Share Analysis, by Sales Channel, 2018 and 2027
FIG. 65 Latin America Cardiac Arrest Treatment Market Attractiveness, by Sales Channel, 2019–2027
FIG. 66 Middle East & Africa Cardiac Arrest Treatment Market Value (US$ Mn) Forecast, 2017–2027
FIG. 67 Middle East & Africa Cardiac Arrest Treatment Market Value Share, by Country/Sub-region, 2018 and 2027
FIG. 68 Middle East & Africa Cardiac Arrest Treatment Market Attractiveness, by Country/Sub-region, 2019–2027
FIG. 69 Middle East & Africa Cardiac Arrest Treatment Market Value Share Analysis, by Treatment, 2018 and 2027
FIG. 70 Middle East & Africa Cardiac Arrest Treatment Market Attractiveness, by Treatment, 2019–2027
FIG. 71 Middle East & Africa Cardiac Arrest Treatment Market Value Share Analysis, by Drugs, 2018 and 2027
FIG. 72 Middle East & Africa Cardiac Arrest Treatment Market Value Share Analysis, by Medical Devices, 2018 and 2027
FIG. 73 Middle East & Africa Cardiac Arrest Treatment Market Value Share Analysis, by Sales Channel, 2018 and 2027
FIG. 74 Middle East & Africa Cardiac Arrest Treatment Market Attractiveness, by Sales Channel, 2019–2027
FIG. 75 Global Cardiac Arrest Treatment Drugs Market Share Analysis, by Company (2018)
FIG. 76 Global Cardiac Arrest Treatment Medical Devices Market Share Analysis, by Company (2018)
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Cardiac Arrest Treatment Market Insights, 2019-2027
